Aditxt Inc. (NASDAQ:ADTX) announced it has acquired Ignite Proteomics LLC, a precision oncology company specializing in functional proteomics technology used to guide cancer treatment decisions, according to a company press release.
The deal assigns Ignite a stated value of $36 million, with Aditxt issuing 36,000 shares of newly created Series A-2 Convertible Preferred Stock as consideration. Ignite will operate as a subsidiary within Aditxt’s oncology-focused business initiatives. The acquisition comes as Aditxt currently holds a market capitalization of roughly $640,000.
Ignite operates a CLIA-certified laboratory and has secured a Medicare Proprietary Laboratory Analyses reimbursement pathway valued at approximately $2,200 per test. Its Reverse Phase Protein Array (RPPA) platform evaluates protein expression and functional activity within tumors, offering a different approach from traditional genomic testing that focuses on identifying DNA mutations.
The company plans to introduce a program in 2026 aimed at the more than 600,000 patients in the United States living with metastatic cancer who have limited treatment options. Ignite estimates that the addressable market for its services could reach about $3 billion, particularly among patients eligible for antibody-drug conjugates and other targeted therapies.
Aditxt’s stock has shown significant volatility, declining nearly 100% over the past year and falling 57% year-to-date.
Ignite has already established research collaborations with several major medical institutions. In September 2025, the company partnered with Inova Health to analyze up to 600 tumor samples from patients with late-stage gastrointestinal cancers using its proteomics platform. Ignite is also collaborating with the Dana-Farber Cancer Institute at Harvard and Vanderbilt University Medical Center.
At the 2025 NCCN Annual Conference, Ignite presented findings from the I-SPY 2 clinical trial, showing that MHC-II protein expression, measured through its platform, outperformed five PD-L1 assays as a predictor of response to the immunotherapy pembrolizumab.
The platform measures 32 phospho- and total-protein biomarkers from tumor biopsy samples. Ignite also operates a CAP-accredited laboratory and holds licensed intellectual property supporting its technology.
Additional developments
In other recent updates, Aditxt announced plans to implement a 1-for-8 reverse stock split of its common shares, which took effect at the opening of trading on March 9. The move was approved by shareholders during a special meeting held on February 13, 2026.
The company also postponed its special shareholder meeting to February 13, 2026, allowing additional time for investors to vote on several proposals. These include approvals related to the issuance of common stock underlying Series A-1 and Series C-1 Convertible Preferred Stock, as well as certain stock purchase warrants.
Shareholders are also scheduled to vote on the 2025 Employee Stock Purchase Plan and proposed amendments to the 2021 Omnibus Equity Incentive Plan.
Separately, Aditxt has received an extension from Nasdaq to regain compliance with Listing Rule 5550(b) after the exchange reviewed the company’s compliance plan submitted on January 15.